FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387360665> ?p ?o ?g. }

• W4387360665 abstract "Abstract Background The efficacy of pembrolizumab monotherapy in metastatic castration-resistant prostate cancer patients when stratified by MSI-H and/or TMB-H is poorly defined. Additionally, outcomes based on sequencing source ( i.e. , tissue or liquid biopsy) have not been well described. We sought to assess outcomes of pembrolizumab monotherapy in patients with mCRPC and compare efficacy based on MSI-H and/or TMB-H when identified by tissue or liquid biopsy. Methods A retrospective analysis was performed of mCRPC patients treated at Mayo Clinic with pembrolizumab monotherapy between 2018 and 2023. Objective response rates (ORR), median progression-free survival (mPFS), and overall survival (mOS), were determined by RECIST v1.1 criteria. Results Twenty-two patients with mCRPC received pembrolizumab monotherapy for at least 3 cycles for an MSI-H or TMB-H indication. All patients had next generation sequencing (NGS) performed via tissue (n = 11) or liquid (n = 10) biopsy source. The ORR was 50% (27.3% complete response and 22.7% had partial response). The mPFS for TMB 10-14.9 mut/Mb (n = 4), TMB 15-24.9 mut/Mb (n = 6), and TMB ≥ 25 mut/Mb (n = 10) was 2.1, not reached (NR), and NR, respectively (p = 0.0003). The mOS for these same groups was 5.1 months, 20.5 months, and not reached, respectively. Among patients with TMB-H without co-occurring MSI-H or CDK12 (n = 6), none experienced a response and only one patient had stable disease compared to patients with MSI-H (n = 12) for whom the ORR was 75%. Immunotherapy responsive alterations such as ATRX and PTCH1 mutations were frequently noticed among patients who had complete response (CR). Conclusions Our study highlights that MSI-H drives the efficacy of pembrolizumab in mCRPC with better survival outcomes as TMB increases. Clinicians should consider alternative treatment strategies for advanced prostate cancer when TMB-H is present without co-occurring MSI-H or CDK12. This study further demonstrates the utility of liquid biopsy NGS for identifying MSI-H and/or TMB-H disease." @default.
• W4387360665 created "2023-10-06" @default.
• W4387360665 creator A5005887623 @default.
• W4387360665 creator A5006833753 @default.
• W4387360665 creator A5016092330 @default.
• W4387360665 creator A5025890579 @default.
• W4387360665 creator A5030233600 @default.
• W4387360665 creator A5064130895 @default.
• W4387360665 creator A5076737381 @default.
• W4387360665 creator A5082402405 @default.
• W4387360665 date "2023-10-05" @default.
• W4387360665 modified "2023-10-06" @default.
• W4387360665 title "A Real-World Experience of Pembrolizumab Monotherapy in Microsatellite Instability-High and/or Tumor Mutation Burden-High Metastatic Castration-Resistant Prostate Cancer: Outcome Analysis" @default.
• W4387360665 cites W1975577875 @default.
• W4387360665 cites W2150865892 @default.
• W4387360665 cites W2296253991 @default.
• W4387360665 cites W2373606074 @default.
• W4387360665 cites W2606495925 @default.
• W4387360665 cites W2763584377 @default.
• W4387360665 cites W2838357484 @default.
• W4387360665 cites W2990771207 @default.
• W4387360665 cites W3048671838 @default.
• W4387360665 cites W3083986479 @default.
• W4387360665 cites W3103673446 @default.
• W4387360665 cites W3136653115 @default.
• W4387360665 cites W3164448920 @default.
• W4387360665 cites W3172043565 @default.
• W4387360665 cites W3187644677 @default.
• W4387360665 cites W3210347387 @default.
• W4387360665 cites W4220869779 @default.
• W4387360665 cites W4283030292 @default.
• W4387360665 cites W4297903474 @default.
• W4387360665 doi "https://doi.org/10.21203/rs.3.rs-3382530/v1" @default.
• W4387360665 hasPublicationYear "2023" @default.
• W4387360665 type Work @default.
• W4387360665 citedByCount "0" @default.
• W4387360665 crossrefType "posted-content" @default.
• W4387360665 hasAuthorship W4387360665A5005887623 @default.
• W4387360665 hasAuthorship W4387360665A5006833753 @default.
• W4387360665 hasAuthorship W4387360665A5016092330 @default.
• W4387360665 hasAuthorship W4387360665A5025890579 @default.
• W4387360665 hasAuthorship W4387360665A5030233600 @default.
• W4387360665 hasAuthorship W4387360665A5064130895 @default.
• W4387360665 hasAuthorship W4387360665A5076737381 @default.
• W4387360665 hasAuthorship W4387360665A5082402405 @default.
• W4387360665 hasBestOaLocation W43873606651 @default.
• W4387360665 hasConcept C104317684 @default.
• W4387360665 hasConcept C121608353 @default.
• W4387360665 hasConcept C126322002 @default.
• W4387360665 hasConcept C143998085 @default.
• W4387360665 hasConcept C180754005 @default.
• W4387360665 hasConcept C2775934546 @default.
• W4387360665 hasConcept C2777701055 @default.
• W4387360665 hasConcept C2779529041 @default.
• W4387360665 hasConcept C2779767149 @default.
• W4387360665 hasConcept C2780057760 @default.
• W4387360665 hasConcept C2780192828 @default.
• W4387360665 hasConcept C55493867 @default.
• W4387360665 hasConcept C61320498 @default.
• W4387360665 hasConcept C71924100 @default.
• W4387360665 hasConcept C86803240 @default.
• W4387360665 hasConceptScore W4387360665C104317684 @default.
• W4387360665 hasConceptScore W4387360665C121608353 @default.
• W4387360665 hasConceptScore W4387360665C126322002 @default.
• W4387360665 hasConceptScore W4387360665C143998085 @default.
• W4387360665 hasConceptScore W4387360665C180754005 @default.
• W4387360665 hasConceptScore W4387360665C2775934546 @default.
• W4387360665 hasConceptScore W4387360665C2777701055 @default.
• W4387360665 hasConceptScore W4387360665C2779529041 @default.
• W4387360665 hasConceptScore W4387360665C2779767149 @default.
• W4387360665 hasConceptScore W4387360665C2780057760 @default.
• W4387360665 hasConceptScore W4387360665C2780192828 @default.
• W4387360665 hasConceptScore W4387360665C55493867 @default.
• W4387360665 hasConceptScore W4387360665C61320498 @default.
• W4387360665 hasConceptScore W4387360665C71924100 @default.
• W4387360665 hasConceptScore W4387360665C86803240 @default.
• W4387360665 hasLocation W43873606651 @default.
• W4387360665 hasOpenAccess W4387360665 @default.
• W4387360665 hasPrimaryLocation W43873606651 @default.
• W4387360665 hasRelatedWork W2062691140 @default.
• W4387360665 hasRelatedWork W2517747645 @default.
• W4387360665 hasRelatedWork W2521234799 @default.
• W4387360665 hasRelatedWork W2585407512 @default.
• W4387360665 hasRelatedWork W2891524425 @default.
• W4387360665 hasRelatedWork W2945780494 @default.
• W4387360665 hasRelatedWork W3037068108 @default.
• W4387360665 hasRelatedWork W3041652591 @default.
• W4387360665 hasRelatedWork W4200023723 @default.
• W4387360665 hasRelatedWork W4281564228 @default.
• W4387360665 isParatext "false" @default.
• W4387360665 isRetracted "false" @default.
• W4387360665 workType "article" @default.